Rashid OM, Nagahashi M, Ramachandran S, Yamada A, Graham L, Milstien S, Spiegel S, Bear HD, Takabe K. Resection of the Primary Tumor Improves Survival in Metastatic Breast Cancer by Reduction of
Overall Tumor Burden.
Understanding a patient's
overall tumor burden through genomic testing, says Carbone, could help identify patients most likely to benefit from immunotherapy before therapy ever begins.
Not exact matches
Benefits include reduction of
tumor burden, delayed cancer progression, and
overall improvement in survival in some cases.
In animal models, the modified T cells greatly reduced the
tumor burden and prolonged
overall survival: All mice that received the modified T cells were alive 44 days after treatment versus 29 percent and 17 percent of the study's two control groups.
Excitingly, a single dose of any of the three NK cell populations assessed led to a significant reduction in
tumor burden, although the iPSC ‐ derived NK group demonstrating a trend toward
overall better activity.
In addition to monitoring
overall survival, we assessed
tumor burden, as measured by bioluminescence imaging, during the first 22 days of treatment (Figure 3).
This included evaluation of
tumor burden in mice orthotopically xenografted, as well as analysis of the
overall rate of survival.